Jie Dong1, Xiao-Feng Yu, Jian Zou. 1. Department of Gastroenterology, Huadong Hospital, Fudan University, 221 Yan An Xi Road, Shanghai 200040, China.
Abstract
AIM: To evaluate whether adding azithromycin to first-line Helicobacter pylori (H pylori) eradication improved eradication and reduced side effects. METHODS: Eligible articles were identified by searches of electronic databases. We included all randomized trials that compared azithromycin-containing with standard triple-therapy regimens for first-line treatment of H pylori infection. Statistical analysis was performed with Review Manager 5.0.10. Sub-analyses were also performed. RESULTS: We identified 14 randomized trials (1431 patients). Pooled H pylori eradication rates were 72.01% (95% CI: 58.09%-85.93%) and 69.78% (95% CI: 66.47%-73.09%) for patients with or without azithromycin by intention-to-treat analysis, and the odds ratio (OR) was 1.17 (95% CI: 0.64-2.14). The occurrence of side effects differed significantly and was 15.81% (95% CI: 12.50%-19.12%) and 25.20% (95% CI: 21.44%-28.96%) for treatment with or without azithromycin, respectively, and the summary OR was 0.58 (95% CI: 0.41-0.82). Furthermore, the azithromycin-containing group had a lower occurrence of diarrhea, nausea and taste disturbance. CONCLUSION: Our review suggests that azithromycin-containing triple-therapy regimens could be equally effective in eradication of H pylori compared with standard first-line triple-therapy regimens.
AIM: To evaluate whether adding azithromycin to first-line Helicobacter pylori (H pylori) eradication improved eradication and reduced side effects. METHODS: Eligible articles were identified by searches of electronic databases. We included all randomized trials that compared azithromycin-containing with standard triple-therapy regimens for first-line treatment of H pylori infection. Statistical analysis was performed with Review Manager 5.0.10. Sub-analyses were also performed. RESULTS: We identified 14 randomized trials (1431 patients). Pooled H pylori eradication rates were 72.01% (95% CI: 58.09%-85.93%) and 69.78% (95% CI: 66.47%-73.09%) for patients with or without azithromycin by intention-to-treat analysis, and the odds ratio (OR) was 1.17 (95% CI: 0.64-2.14). The occurrence of side effects differed significantly and was 15.81% (95% CI: 12.50%-19.12%) and 25.20% (95% CI: 21.44%-28.96%) for treatment with or without azithromycin, respectively, and the summary OR was 0.58 (95% CI: 0.41-0.82). Furthermore, the azithromycin-containing group had a lower occurrence of diarrhea, nausea and taste disturbance. CONCLUSION: Our review suggests that azithromycin-containing triple-therapy regimens could be equally effective in eradication of H pylori compared with standard first-line triple-therapy regimens.
Authors: G Cammarota; A Papa; R Cianci; O Cannizzaro; A Armuzzi; A Gasbarrini; G Addolorato; G B Gasbarrini Journal: Eur J Gastroenterol Hepatol Date: 1999-03 Impact factor: 2.566
Authors: Vladimir T Ivashkin; Tatiana L Lapina; Oksana Yu Bondarenko; Olga A Sklanskaya; Petr Ya Grigoriev; Yuri V Vasiliev; Emilia P Yakovenko; Pavel V Gulyaev; Valeri I Fedchenko Journal: World J Gastroenterol Date: 2002-10 Impact factor: 5.742
Authors: Adam F M Stone; Michael A Mendall; Juan-Carlos Kaski; Tracey M Edger; Paul Risley; Jan Poloniecki; A John Camm; Timothy C Northfield Journal: Circulation Date: 2002-09-03 Impact factor: 29.690
Authors: Seung Won Ra; Marc A Sze; Eun Chong Lee; Sheena Tam; Yeni Oh; Nick Fishbane; Gerard J Criner; Prescott G Woodruff; Stephen C Lazarus; Richard Albert; John E Connett; Meilan K Han; Fernando J Martinez; Shawn D Aaron; Robert M Reed; S F Paul Man; Don D Sin Journal: Respir Res Date: 2017-05-30